23ME-00610 as a monotherapy showed one partial response in a patient with clear-cell renal cell carcinoma, while 23ME-01473 ...

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in ...

supplements and medications on cancer prevention and treatment both in a xenograft mouse model and in vitro; Diet effects on antioxidant status and the development oxidative stress and its ...

This was further validated in an HCC xenograft mouse model, where the combination of shCD39-CAR-T cells with mdivi-1 resulted ...

We defined a combination therapy that can block both ER and RAS. When given to a xenograft mouse model derived from a patient who failed several lines of anti-ER therapies, the ER/RAS combination ...

In xenograft mouse models, the combination therapy significantly reduced tumor growth with minimal toxicity, demonstrating its potential as a feasible treatment strategy for cancers harboring wild ...

In a report released today, Silvan Tuerkcan from JMP Securities maintained a Buy rating on Acrivon Therapeutics, Inc. (ACRV – Research ...

AK132 mediates macrophage phagocytosis of CLDN18.2+/CD47+ tumor cells and effectively inhibits tumor growth in subcutaneous xenograft mouse models. AK132 also efficiently kills tumor cells through ...

Ground section of Orthopedic implant Ground section of impanted bone Methylene blue – Basic fuchsin Histology procedures are performed on a broad range of experimental animal models including ... CD31 ...

Following oral administration, CGT6737 demonstrated robust PK/PD and tumor growth inhibition with 90% PD inhibition in mouse xenograft models. Lead optimization of CGT6737 is ongoing. The second ...

Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both ...